Short Courses  |  Day 1 |  Day 2 |  Day 3 |  Download Brochure

Pre-Conference Short Courses*

TUESDAY, FEBRUARY 2

9:00 AM – 12:00 PM

(SC4) ADDRESSING SAFETY CONCERNS FOR BIOLOGICAL DRUGS

• Overview of challenges pertaining to safety for biologics
• Safety assessments at pre-clinical and clinical stage
• Use of new assays, animal models and biomarkers for early predictions

Course Instructor:

Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology,
Abbott Laboratories

(SC5) TARGETING CANCER STEM CELLS WITH BIOLOGICS

• Novel nanoparticle fusion proteins, tr1 and tr4, that achieve normal p21 delivery to p53/p21 mutated tumors (tr1) and inhibition of notch signaling (tr4) resulting in tumor eradication
• Differentiation versus self-renewal: changing cancer stem cell fate by targeting stem cell pathways
• Cancer stem-like cells: isolation using biological criteria and use in drug discovery and development
• Cd47: an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
• Identification of stem cell markers in the normal prostate and prostate cancer
  

Course Instructors:
Agamemnon Epenetos, Ph.D., FRCP, Chairman, Trojantec Ltd.
Austin Gurney, Ph.D., Vice President, Molecular and Cellular Biology, OncoMed Pharmaceuticals, Inc.
Jennie P. Mather, Ph.D., Senior Vice President, Stem Cell Research, MacroGenics, Inc.
Ravi Majeti M.D., Ph.D., Assistant Professor, Division of Hematology, Stanford Cancer Center, Institute for Stem Cell Biology and Regenerative Medicine
Kevin G. Leong, Ph.D., Scientist, Tumor Biology and Angiogenesis, Genentech, Inc.

*Separate Registration Required.

Short Courses  |  Day 1 |  Day 2 |  Day 3 |  Download Brochure